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Background. In developing countries, introduction of pneumococcal conjugate vaccine has not eliminated circulation of vaccine 
serotypes. Vaccinating pregnant mothers to increase antibody concentrations in their newborn infants may reduce the acquisition 
of pneumococcal carriage and subsequent risk of disease. We explored the efficacy of passive immunity, attributable to anti-protein 
and anticapsular pneumococcal antibodies, against acquisition of carriage.
Methods. We examined the rate of nasopharyngeal acquisition of pneumococci in the first 90 days of life associated with varying 
anticapsular and anti-protein antibody concentrations in infant cord/maternal venous blood in Kilifi, Kenya. We used multivariable 
Cox proportional hazard models to estimate continuous functions relating acquisition of nasopharyngeal carriage to the concentra-
tion of maternally derived antibody.
Results. Cord blood or maternal venous samples were collected from 976 mother-infant pairs. Pneumococci were acquired 561 
times during 33,905 person-days of follow-up. Increasing concentrations of anti-protein antibodies were associated with either a 
reduction (PhtD1, PspAFam2, Spr0096, StkP) or, paradoxically, an increase (CbpA, LytC, PcpA, PiaA, PspAFam1, RrgBT4) in acqui-
sition rate. We observed a nonsignificant reduction in the incidence of homologous carriage acquisition with high concentrations of 
maternally derived anticapsular antibodies to 5 serotypes (6A, 6B, 14, 19F, and 23F).
Conclusion. The protective efficacy of several anti-protein antibodies supports the strategy of maternal vaccination to protect 
young infants from carriage and invasive disease. We were not able to demonstrate that passive anticapsular antibodies were pro-
tective against carriage acquisition at naturally occurring concentrations though it remains possible they may do so at the higher 
concentrations elicited by vaccination.
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Among infants in low-income countries, pneumococcal car-
riage is acquired rapidly. In Kenya, in the prevaccination era, 
more than 80% of newborns acquired nasopharyngeal carriage 
by the age of 90 days [1]. The median time to colonization was 
45 days in Thailand [2], whereas in India 54% of infants aged 
2 months carried pneumococci [3]. Colonization is an essen-
tial step in the pathway to invasive pneumococcal disease (IPD) 
[4]. In a prevaccine surveillance exercise in Kilifi, Kenya, 15% of 
IPD episodes occurred in the first 2 months of life [5].
Pneumococcal conjugate vaccine (PCV) has been introduced 
in many low-income countries in schedules where infants are 
first vaccinated at either 6 weeks or 2  months of age [6]. In 
addition to direct protection of the vaccinated infant, the vac-
cine provides herd protection to unvaccinated individuals by 
interrupting transmission [7]. However, in contrast to devel-
oped countries [8], herd protection has not eliminated the 
circulation of vaccine serotypes in low-income countries, and 
evidence from Kenya [9] and The Gambia [10] suggests that the 
prevalence of vaccine serotypes remains relatively high several 
years after vaccine introduction.
This justifies the evaluation of maternal or newborn vaccina-
tion as strategies to protect young infants. Newborn vaccination 
with the 7-valent PCV was safe and immunogenic in Kenya and 
Papua New Guinea [11, 12]. In a review of studies of mater-
nal vaccination, no safety concerns were reported with the 
23-valent pneumococcal polysaccharide vaccine (PPV-23) or 
in the only study of maternal vaccination with a 9-valent PCV 
[13, 14]. Vaccination increased the passive transfer of antibod-
ies to newborns, more so with the PCV [13]. Protein and whole 
cell pneumococcal vaccines, currently in clinical development, 
are designed to protect recipients against all serotypes of pneu-
mococcus [15] and could be used, potentially, to protect young 
infants through newborn or maternal vaccination.
The correlates of protection (CoP) against invasive pneu-
mococcal disease (IPD) have been established [16]. Attempts 
to derive CoP for vaccine-induced protection against carriage 
M A J O R  A R T I C L E
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of 
America.  This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/cix742
Received 5 May 2017; editorial decision 7 August 2017; accepted 11 August 2017.
Correspondence: J. Ojal, P.O Box 230–80108, Kilifi, Kenya.(jojal@kemri-wellcome.org).
Clinical Infectious Diseases®  2017;XX(00):1–10
OA-CC-BY
XX
XXXX
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix742/4083657
by London School of Hygiene & Tropical Medicine user
on 27 November 2017
2 • CID 2017:XX (XX XXXX) • Ojal et al
have not provided a clear-cut threshold [17, 18]. In addition, 
previous studies of this relationship have been constrained by 
several methodological limitations.
Most studies, for example, relating newborn colonization to 
maternally derived antibodies, with [19, 20] or without mater-
nal vaccination [21–23], have failed to account for the coloni-
zation status of the mother at birth. Children born to carrier 
mothers have a higher risk of infection by the mother and are 
also likely to receive higher antibody concentrations by passive 
transfer, thus confounding the relationship between antibody 
concentration and carriage.
Second, the ascertainment of carriage acquisition in infants 
has been relatively insensitive. The earliest swabs were obtained 
at no younger than 1  month of age [20–25], and the period 
between subsequent swabs was also at least a month in all of the 
studies. Third, previous studies have been undermined by the 
relatively small sample sizes, which limits the power to detect 
modest protective efficacies. Clinical trials of maternal vacci-
nation studied samples of both vaccinated and control children 
ranging in size from 46 to 437 infants [14], and studies with-
out maternal vaccination had sample sizes in the range 51–310 
[21–23, 25]. Finally, only one previous study has measured both 
anticapsular and anti-protein antibodies in the mother-infant 
pairs, and even here they were assessed independently [25].
Understanding the association between maternally derived 
antibodies and the rate of carriage acquisition for a panel of 
pneumococcal proteins and capsular polysaccharides is likely to 
guide antigen selection in future maternal/newborn immuniza-
tion strategies. We aimed to characterize this association using a 
study where the carriage status of the mother at birth is already 
known; the ascertainment of carriage in the infant begins early 
and recurs frequently; the study population is of sufficient size 
to detect moderate associations; and the effects of anti-protein 
and anticapsular antibodies are analyzed simultaneously to 
determine the independent protective efficacies of each.
METHODS
Data
The study population and design have been described in detail 
elsewhere [1]. The study was conducted before the introduction 
of PCV vaccination in Kenya. Briefly, we collected nasopharyn-
geal swab specimens from participating newborns, aged at most 
7 days, twice weekly for 2 weeks, and weekly thereafter until a 
pneumococcus was cultured from an infant’s swab or until 13 
weeks after study entry, whichever was sooner. Mothers were 
swabbed at the time of birth and monthly thereafter. Cord blood 
was collected at the time of birth if the delivery took place at 
the hospital. Venous blood was collected from the mother if the 
child was born at home and reported to hospital within 7 days.
The environmental risk factors for carriage ascertained were: 
sex, mother’s HIV status, history of cough, history of coryza, 
observed cough, observed coryza, observed runny nose and 
breastfeeding status. At the household level we ascertained: type 
of fuel used for cooking, number of siblings aged <10  years, 
number of other children aged <10  years, number of adults, 
number of smokers, and number of carers.
Laboratory Methods
A direct binding electrochemiluminescence-based multiplex 
assay [26] was used to measure serum immunoglobulin G (IgG) 
antibodies to 27 pneumococcal protein antigens. Pneumococcal 
reference serum 007sp was used as a standard and assigned a 
value of 1000 arbitrary units for each antigen [27]. Antibody 
levels in serum samples were expressed as concentrations with 
reference to the amount in 007sp.
We used enzyme-linked immunosorbent assay (ELISA) to 
analyze serum samples for antibodies to 6A, 6B, 14, 19F, and 
23F capsular polysaccharides as described previously [28]. The 
assays were done at the World Health Organization (WHO) 
reference laboratory for pneumococcal serology, University 
College London Institute of Child Health, UK. These 5 sero-
types were chosen because they were the serotypes most fre-
quently acquired in the study.
Statistical Analysis
Univariable Cox proportional hazard (Cox PH) models were fit-
ted to assess the relationship between the hazard of acquisition 
of carriage and anti-protein antibody concentrations for each 
of the 27 proteins. Nonlinear effects of antibodies were mod-
eled using restricted cubic splines [29]. The univariable Cox PH 
models were also fitted for homologous carriage against sero-
type-specific anticapsular antibody concentrations. Subjects 
were censored upon acquiring any pneumococcal serotype. 
For serotype-specific analyses this introduces a competing-risk 
scenario. Therefore, instead of estimating the standard hazard 
rates, we estimated the cause-specific hazard rates [30].
The principal problem with serotype-specific analyses is 
power, because only a subset of all pneumococcal acquisitions 
is used. We replicated timespan records for each individual 4 
times resulting in 5 copies. We then associated each replicate 
record with a standardized log IgG concentration, as well as 
an indicator for acquisition, for each of the 5 serotypes. The 
log IgG concentrations were standardized using serotype-spe-
cific means and standard deviations. This restructured data 
set allowed us to estimate the impact of anticapsular antibodies 
on the acquisition of any of the 5 serotypes in a single model. 
We calculated cluster robust standard errors to account for the 
correlation introduced by replication.
We used the least absolute shrinkage and selection operator 
(LASSO) penalty to select anti-protein antibodies and environ-
mental risk factors to retain in multivariable Cox PH models. 
We assumed that these factors were independent of serotype and 
therefore examined their effect by fitting a penalized Cox PH 
model with acquisition of any pneumococcus as outcome. The 
LASSO procedure shrinks the coefficients of the less relevant 
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variables to zero and results in a set of variables that have opti-
mal predictive value. Simulations indicate that the LASSO pro-
cedure can be more accurate than stepwise selection [31]. In the 
presence of strong correlations between candidate predictors, 
the LASSO may not be consistent in variable selection [32]. 
Consistency here refers to a higher ability to recover the correct 
model with growing number of observations. To achieve consist-
ency we used an ensemble voting approach [33]. This involved 
fitting the penalized model to the observed data set and across 
200 bootstrap-resampled data sets, and using this pool of esti-
mated coefficients to vote on which variables to include in the 
model. A variable was selected if its coefficient was not reduced 
to zero in more than 50% of the resampled data sets, a threshold 
that is a balance between being too restrictive or too lenient.
We estimated nonlinear effects on acquisition of any serotype of 
each selected anti-protein antibody adjusting for selected environ-
mental variables and remaining selected protein variables. All the 
Cox PH models of the effect of anticapsular IgG on the hazard of 
serotype-specific acquisition were adjusted for the selected envi-
ronmental and protein variables. In these models, we entered the 
anticapsular or anti-protein IgG coefficient of interest unpenalized 
unlike the rest of the predictors used in adjustment. We also esti-
mated nonlinear effects on acquisition of the 5 serotypes of each 
selected protein antibody adjusting for selected environmental var-
iables, the remaining selected protein variables and the standard-
ized anticapsular antibodies. Anticapsular concentrations below 
the minimum detectable limit of 0.15 mcg/mL were imputed as 
half the value, that is, 0.15/2 = 0.075. All anti-protein and anticap-
sular concentrations were log-transformed before analysis.
RESULTS
Acquisition Rates
Cord or venous blood samples were collected from 976 newborns; 
342 (35%) of these were venous blood. The newborns were fol-
lowed for a total of 33,905 days resulting in 561 acquisitions of 
pneumococcus; 218 (39%) of these were for serotypes 6A, 6B, 
14, 19F, and 23F. The rate of acquisition per infant per 1000 days 
ranged from 0.77 for serotype 14 to 2.18 for serotype 19F (Table 1).
Univariable Analyses
Higher levels of anti-protein IgG were associated with reduction 
in acquisition of any serotype for a number of proteins; nearly 
monotonic relations between acquisition hazard and IgG level 
were estimated for PhtD1, PhtD2, PhtE, and StkP (P > .15 for 
each). Higher anti-protein antibodies to PiaA, RrgBT4, RrgB6B, 
and RrgB23F were associated with increased acquisition of car-
riage (P < .033 for each) (Figure S1).
The serotype-specific hazard of acquisition as a function of 
homologous log IgG concentration did not show a monotoni-
cally decreasing trend with higher concentrations (Figure 1). For 
serotypes 14 and 19F, there was favorable reduction in acquisi-
tion hazard at higher IgG levels. In the joint analysis combining 
all 5 serotypes, higher anticapsular IgG concentrations, on the 
extreme right of the distribution of IgG concentrations, were 
associated with a reduction in acquisition (Figure 2); however, 
we did not find evidence of an association across the whole 
range of values (P = .797). The point-wise confidence intervals 
(CIs) in the figures, at the upper bound descends below the haz-
ard ratio (HR) of 1; this can be used to mark log IgG levels, 
which result in a significant reduction in carriage rates com-
pared to typical (mean) log IgG values. In the univariable analy-
sis, the upper limits of the CIs are all above a HR of 1.
Multivariable Analyses
Table 2 shows the set of environmental and anti-protein anti-
body variables selected by the lasso procedure. In the set of 
candidate environmental predictors, sex, history of cough, 
observed cough, observed runny nose, and breastfeeding status 
were voted out of the model. Among the 27 candidate anti-pro-
tein antibody predictors, 17 were voted out. Except for antibod-
ies to PhtD1, PspAFam2, StkP, and Spr0096, in which higher 
concentrations were associated with reduction in carriage 
acquisition, higher IgG levels for the remaining proteins were 
associated with increased acquisition (Table  2). The group of 
newborns who were born in hospital had a lower rate of pneu-
mococcal acquisition (18% lower) compared to newborns who 
were born at home (Table 2).
Among the 10 proteins in which adjusted nonlinear effects 
on carriage acquisition were analyzed, higher concentrations of 
PhtD1 and StkP were associated (P =  .020 and 0.036, respec-
tively) with reduced acquisition. Higher concentrations of 
RrgBT4 were associated (P = .003) with an increase in acquisi-
tion rate for the greater part of the distribution of anti-RrgBT4 
antibodies (Figure 3). The function for anti-RrgBT4 concentra-
tion was nonmonotonic; we also observed higher carriage rates 
in the lower tail of the distribution. The effects of the anti-pro-
tein concentration on acquisition of any of the 5 serotypes with-
out adjusting for the anticapsular concentrations (Figure S2) 
were similar with adjustment (Figure S3).
Adjusting for environmental and anti-protein antibody vari-
ables in the models of the effect of serotype-specific anticapsular 
Table 1. Acquisitions Rates of Serotypes
Serotype Acquisitions
Incidence
(per 1000 days) 95% CI
Incidence in larger 
cohorta
(per 1000 days)
6A 45 1.33 0.97–1.77 1.49
6B 38 1.12 0.79–1.54 1.26
14 26 0.77 0.50–1.12 0.79
19F 74 2.18 1.71–2.74 2.54
23F 35 1.03 0.72–1.44 1.24
The total time at risk was 33,905 person-days.
Abbreviation: CI, confidence interval.
aThe incidence estimated from the cohort of 1400 that included all newborns; those who 
gave and those who did not give serum samples.
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Figure 1. Univariable analysis of the effect of anti-capsular IgG on serotype-specific carriage acquisition rate. The figure shows the relative hazard of acquisition (blue 
solid line) as a function of log IgG concentration (x-axis) for each serotype labeled above the graph. The hazard at each level of log IgG is relative to the mean log IgG. The 
red dashed lines are the 95%CI bounds of the hazard ratio. The 3 vertical (gray) lines mark the 2.5th, 50th and 97.5th percentiles of the distribution of log IgG whose density 
is shown in grey on the x-axis. The likelihood ratio (LR) test P-value compares a model with and that without the log IgG concentration variable, thus indicating the overall 
significance of antibody concentration. The point-wise confidence intervals in the figures, at the point where the upper bound descends below the hazard ratio of 1, can be 
used to mark log IgG levels which results in significant reduction in carriage rates compared to typical (mean) log IgG values. Abbreviation: IgG, immunoglobulin G. 
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antibodies only marginally influenced the shape of the hazard 
functions compared to the unadjusted analyses. In serotype 
19F there was lower risk in the upper tail of the distribution of 
IgG concentration; however, there was no evidence an overall 
effect of serotype-specific IgG (P = .13–0.97) (Figure 4). In the 
joint multivariable analysis of all 5 serotypes, individuals with 
standardized log IgG concentration of about 2 and above had 
significant reduction in the rate of acquisition, by 50% or more, 
compared to individuals with the average standardized log IgG 
(Figure 2, right panel). A  standardized log IgG concentration 
of 2 is equivalent to an absolute IgG concentration of 11.1, 9.8, 
3.1, 5.5, and 19.0 mcg/mL for serotypes 6A, 6B, 14, 19F, and 23F, 
respectively.
DISCUSSION
We assessed the association between maternally derived 
anti-protein and anticapsular antibodies and the rate of car-
riage-acquisition in the first 90 days of life among mother-in-
fant pairs in the prevaccination period in Kenya. Among 
anti-protein antibodies, we found that higher concentrations 
Figure 2. Univariable (upper panel) and Multivariable (lower panel) analysis of the effect of anti-capsular IgG concentration on carriage acquisition rates of any of the 
serotypes: 6A, 6B, 14, 19F and 23F. The figure follows the convention described in the legend for Figure 1. The 95% CIs for the multivariable analysis are percentile-based 
and computed from 200 cluster bootstrap (clustered on subject/individual) resamples of the data. PLR stands for penalized likelihood ratio test, comparing a model with the 
log IgG concentration variable and one without. Abbreviations: CI, confidence interval; IgG, immunoglobulin G.
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of antibody to some proteins (PhtD1, PspAFam2, Spr0096, and 
StkP) were associated with a reduction in the acquisition rate 
but, unexpectedly, other proteins (CbpA, LytC, PcpA, PiaA, 
PspAFam1, and RrgBT4) were associated with an increase in 
acquisition rate (Figure 3).
Some of the associations are consistent with our understand-
ing of the protein functions. For instance, higher anti-protein 
antibodies to histidine triad protein (PhtD) were significantly 
associated with a reduction in acquisition. PhtD is a pneumo-
coccal cell surface protein that contributes to the adherence 
of S. pneumoniae to epithelial cells [34]. This protein has been 
used as a vaccine candidate [35].
Several associations are apparently inconsistent with known 
functions of the proteins. The presence of pilus has been impli-
cated in adhesion to epithelial cells in humans and mice [36], 
suggesting a role in colonization. RrgB is a backbone subunit of 
pneumococcus pilus-1; anti-RrgBT4 antibody binding to pilus 
might reduce its capacity to bind epithelial cells and thereby 
abrogate its role in adhesion. Therefore, higher anti-RrgBT4 
concentrations would result in lower carriage acquisition. 
The pneumococcal serine threonine protein kinase (StkP) has 
recently been shown to repress the expression of pilus and mod-
ulate bacterial adherence to human epithelial cells [37]. Thus, 
higher anti-StkP antibodies imply impaired repression of the 
pilus in the pneumococcus enhancing the attachment capacity 
of the bacterium, leading to increased carriage acquisition.
However, we observed a nonmonotonic relation between car-
riage acquisition anti-RrgBT4 concentrations; the hazard was 
higher at the lower and upper extremes of the concentration 
scale. We also observed a significant reduction in acquisition 
rate with increasing anti-StkP concentrations (Figure  3). The 
pilus is only expressed in 30–50% of pneumococci [38]; there-
fore, any effect mediated through pilus is likely to be diluted, 
thus the observed effect of anti-RrgBT4 and anti-StkP antibod-
ies might not be entirely explained through their effect on the 
pilus. We did not determine pilus phenotypes of pneumococci 
isolated in this study, so we were unable to include the phenotype 
in our analysis. Nonetheless, StkP is a global kinase involved in 
regulating a number of pneumococcal functions that are critical 
for the resistance of pneumococcus to various stress conditions; 
one such function is cell wall biosynthesis [39]. Antibodies to 
StkP may inhibit the role it plays in cell wall development, and 
that would lead to a decrease in pneumococcal viability and 
therefore reduced carriage. Some of these paradoxical associa-
tions may be due to the observational nature of the study, where 
it is difficult to control completely for confounding; the findings 
could be tested in an experimental design using nasopharyngeal 
challenge studies in animal models. Understanding both the 
positive and negative impacts of antibodies on adhesion may be 
useful for vaccine design.
Several prior studies have documented the limited role of 
maternally derived antibodies in protecting infants from pneu-
mococcal colonization [21, 22, 40]. Maternal vaccination in the 
third trimester of pregnancy increases the amount of antibody 
passed on to the newborn [20, 41]. However, there is insuffi-
cient evidence that maternal vaccination during pregnancy 
could reduce infant carriage or infections [42].
We observed a reduction in the rate of acquisition associated 
with high levels of maternally derived anticapsular antibodies 
to 5 serotypes even though none of the associations was sta-
tistically significant across the whole range of concentrations 
(Figure 2 and 4). The limited effect of anticapsular antibodies on 
carriage acquisition rates in our study could suggest that these 
antibodies are not effective against carriage acquisition, at least 
Table  2. Adjusted Hazard Ratios Quantifying the Association of 
Acquisition of Any Pneumococcal Serotypes With Selected Environmental 
and Anti-protein Antibody Variables
Variable Hazard ratioa 95% CI
Coryza observed at last visit 1.36 1.03–1.60
History of coryza at last visit 1.20 0.87–1.63
Runny nose at last visit 1.17 0.96–1.51
Fuel used for cooking
 Firewood Ref.
 Charcoal 0.61 0.37–0.94
 Paraffin 0.81 0.67–0.97
 Gas 2.04 1.03–6.48
No. of siblings 1.06 1.01–1.13
No. of carers in household 0.94 0.89–0.99
No. of children aged <10 years in household 1.08 1.01–1.16
No. of smokers in household 1.11 0.97–1.30
Mother positive of carriage around time of birth 1.58 1.06–2.06
Type of sample: Cord vs. venous blood (ref.) 0.82 0.69–0.98
Month of swab
 January Ref.
 February 1.22 0.76–1.87
 March 1.22 0.78–1.94
 April 1.12 0.72–1.64
 May 1.02 0.63–1.53
 June 1.95 1.08–2.92
 July 2.57 1.37–3.64
 August 2.19 1.13–3.17
 September 1.99 1.04–2.71
 October 1.93 1.06–2.79
 November 1.84 1.01–3.27
 December 0.88 0.55–1.32
CbpA 1.17 1.00–1.35
LytC 1.17 1.01–1.32
PcpA 1.13 1.00–1.24
PhtD1 0.79 0.70–0.95
PiaA 1.16 1.02–1.27
PspAFam2 0.85 0.77–0.98
PspAFam1 1.07 0.99–1.19
RrgBT4 1.15 1.05–1.25
Spr0096 0.92 0.85–1.00
StkP 0.88 0.81–0.99
Abbreviations: CI, confidence interval; IgG, immunoglobulin G.
aThe hazard ratios for the anti-protein antibodies should be interpreted as the hazard ratio 
per unit increase in log IgG concentration.
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Figure 3. Multivariable analysis of the effect of the selected anti-protein IgG on all pneumococcal carriage acquisition rates. The figure follows the convention described 
in the legend for Figure 1. The 95% CIs are percentile-based and computed from 200 cluster bootstrap (clustered on subject/individual) resamples of the data. PLR stands for 
penalized likelihood ratio test, comparing a model with the log IgG concentration variable and one without. Abbreviations: CI, confidence interval; IgG, immunoglobulin G.
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in an environment such as Kilifi with a high force of infection. 
However, we did observe a steep reduction in acquisition of car-
riage at very high concentration of antibodies in the range of 
3.1–19.0 mcg/mL across different serotypes, though concentra-
tions this high were attained by only about 3% of the newborn 
population (Figure 2). In other settings the proportion attain-
ing these concentrations at birth might be higher; about 25% 
of newborns had these level of antibodies for serotypes 14 and 
19F in a study of American children [43]. This provides some 
rationale for maternal vaccination, if the vaccine can raise the 
level of transferred antibodies to very high concentrations above 
those observed as a consequence of repeated natural exposure.
There are few analyses of CoP against carriage acquisition for 
anticapsular antibodies. A  value of 5 mcg/mL was associated 
with protection against carriage of serotype 14 [17]. Our anal-
ysis suggests that the CoP is likely to be very high, in the range 
3.1–19.0 mcg/mL. In the only reported study of maternal vacci-
nation with a PCV, the geometric mean concentrations (GMC) 
of anticapsular antibodies in cord-blood of newborns to vacci-
nated mothers were between 3 and 19 times higher, depending 
on serotype, compared to newborns to mothers who received a 
placebo. The GMC in cord-blood among newborns from vacci-
nated mothers ranged between 2.4 and 14.3 mcg/mL [13]. This 
increases the potential of PCVs for use in maternal vaccination.
The serotype-specific rates of acquisition observed among the 
subset of newborns whose cord or maternal venous blood were 
collected were very similar to the total sample of 1400 newborns 
that constituted the original study [1] suggesting that the subset 
Figure 4. Multivariable analysis of the effect of anticapsular IgG on serotype-specific carriage acquisition rate. The figure follows the convention described in the legend 
for Figure 1. The 95% CIs are percentile-based and computed from 200 cluster bootstrap (clustered on subject/individual) resamples of the data. PLR stands for penalized 
likelihood ratio test, comparing a model with the log IgG concentration variable and one without. Abbreviations: CI, confidence interval; IgG, immunoglobulin G.
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analyzed was representative (Table  1). The newborns born in 
hospital had lower rates of pneumococcal acquisition com-
pared to those born at home. The blood type (cord or venous) 
provided was therefore a potential confounder in the relation-
ship between antibodies and carriage acquisition. However, we 
adjusted for blood type in all multivariable models.
In conclusion, we observed a significant association between 
carriage acquisition and several anti-protein antibodies but 
only a limited role for maternally derived anticapsular antibod-
ies, at high concentrations, on serotype-specific acquisition of 
pneumococci. This disparity between anti-protein and anticap-
sular effects may be attributable to differential study power, as 
the anticapsular analyses was restricted to homologous acqui-
sitions but the anti-protein analysis included all acquisitions. 
Nonetheless, a strategy of maternal vaccination to improve 
the level of transferred antibodies and thus protect newborns 
against acquisition of carriage may be successful if vaccine for-
mulation is focused on enhancing specific anti-protein antibod-
ies that are associated with reduced carriage or if the strategy 
induces very high concentrations of anticapsular antibodies, 
above those normally observed in physiological trans-placental 
transfer.
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